Skip to main content
. 2020 Sep 9;2020:9539674. doi: 10.1155/2020/9539674

Table 3.

Comparison of pre- and posttreatment among the groups.

  1 month-baseline 2 months–-baseline 2 months-1 month
G1 G2 G3 G4 P G1 G2 G3 G4 P G1 G2 G3 G4 P
Signs (mean ± SD) TMH (mm) 0.02 ± 0.06 0.02 ± 0.06 −0.01 ± 0.06 0.02 ± 0.07   0.03 ± 0.07 0.01 ± 0.06 0.01 ± 0.05 0.00 ± 0.08   0.01 ± 0.06 −0.01 ± 0.06 0.01 ± 0.08 −0.01 ± 0.06  
TBUTF (s) 0.04 ± 3.49 0.17 ± 2.35 0.69 ± 2.04 0.59 ± 1.76   0.66 ± 3.79 1.42 ± 4.26 1.15 ± 1.57 0.79 ± 2.74   0.62 ± 3.39 1.25 ± 3.42 0.48 ± 1.86 0.66 ± 2.54  
TBUTA (s) 0.46 ± 2.87 0.22 ± 2.50 0.74 ± 1.97 0.43 ± 1.77   0.62 ± 3.38 1.62 ± 3.82 0.97 ± 2.43 1.37 ± 2.67   0.16 ± 2.68 1.40 ± 2.96 0.02 ± 1.51 0.82 ± 2.71  
CNFD (mm/mm2) 2.42 ± 1.75 −0.13 ± 1.66 3.16 ± 1.94ε 3.44 ± 3.55∂ 0.021 3.37 ± 2.60 0.89 ± 1.07 7.39 ± 3.57ε 9.32 ± 3.00∂ 0.001 0.95 ± 1.43 1.03 ± 1.53 4.22 ± 2.83∗ε 4.93 ± 3.21 0.002
Symptoms (mean ± SD, scores) Dryness 0.90 ± 2.11 −0.58 ± 2.52 0.28 ± 3.03 −1.41 ± 3.64# 0.005 0.70 ± 2.39 −0.45 ± 2.96 −0.81 ± 2.37 −1.18 ± 2.65# 0.028 −0.20 ± 2.54 0.13 ± 2.48 −1.81 ± 2.47ε 0.23 ± 2.99∀ 0.015
Foreign body sensation 1.18 ± 3.21 −0.08 ± 3.27 −0.08 ± 3.11 −1.19 ± 3.11# 0.021 1.18 ± 3.38 0.60 ± 3.16 −1.31 ± 3.65 −1.50 ± 5.18# 0.011 0.00 ± 2.65 0.68 ± 3.12 −1.88 ± 3.14ε −0.91 ± 4.25 0.013
Pain −0.45 ± 2.16 0.10 ± 3.57 −0.83 ± 3.17 −1.50 ± 2.51   0.05 ± 3.43 0.18 ± 3.46 −1.38 ± 3.09 −0.91 ± 3.71   0.50 ± 3.21 0.08 ± 3.44 −0.46 ± 2.45 0.91 ± 3.50  
Burning 0.50 ± 3.00 0.15 ± 3.33 0.23 ± 2.28 −1.03 ± 3.03   0.30 ± 2.57 0.68 ± 3.12 0.12 ± 1.93 −0.55 ± 2.44   −0.20 ± 3.39 0.53 ± 2.97 −0.46 ± 2.25 −0.09 ± 1.23  
Watering 0.40 ± 2.91 −0.03 ± 2.11 −0.73 ± 2.41 0.22 ± 1.56   0.38 ± 2.25 0.03 ± 2.79 0.00 ± 3.01 0.55 ± 2.22   −0.03 ± 2.09 0.05 ± 3.39 0.23 ± 3.02 0.41 ± 1.22  
Asthenopia 0.80 ± 3.67 0.48 ± 2.37 0.35 ± 2.66 −0.34 ± 2.72   0.60 ± 3.88 0.00 ± 2.31 −0.31 ± 2.77 0.77 ± 2.41   −0.20 ± 2.15 −0.48 ± 2.54 −1.00 ± 3.20 1.41 ± 2.13 0.009
Blurred vision −1.35 ± 3.08 0.35 ± 4.33 −0.28 ± 3.49 −1.16 ± 2.07   0.05 ± 3.59 0.10 ± 3.89 0.46 ± 1.70 −1.32 ± 2.83   1.40 ± 3.24 −0.25 ± 2.85 1.50 ± 3.48 −0.23 ± 1.85 0.020
Itching −0.25 ± 2.70 0.10 ± 3.95 0.25 ± 3.09 −0.72 ± 2.56   0.30 ± 2.52 1.33 ± 4.37 −0.46 ± 3.11 −0.82 ± 3.06   0.55 ± 1.91 1.23 ± 3.91 0.23 ± 3.18 0.32 ± 1.46  
Increased secretions −0.20 ± 1.14 1.13 ± 3.13 0.05 ± 2.77 −0.38 ± 2.55 0.045 −0.03 ± 2.12 0.85 ± 3.67 0.54 ± 3.85 −0.23 ± 1.90   0.18 ± 1.91 −0.28 ± 2.75 0.54 ± 2.92 0.09 ± 1.19  
Photophobia 0.55 ± 2.23 0.10 ± 3.68 −0.38 ± 1.44 −1.09 ± 2.98   −0.08 ± 2.37 −0.78 ± 3.35 −1.08 ± 2.67 −0.95 ± 2.21   −0.63 ± 1.82 −0.88 ± 2.84 −0.81 ± 1.88 0.50 ± 2.94∂∀  
Total 1.75 ± 13.11 1.73 ± 17.65 −1.13 ± 14.26 −8.59 ± 15.46∂# 0.017 3.38 ± 11.51 2.53 ± 13.08 −4.23 ± 13.60 −6.14 ± 15.06# 0.011 1.63 ± 11.89 0.80 ± 16.35 −3.92 ± 13.11 2.64 ± 8.94  
Satisfaction (mean ± SD, scores) Before −0.57 ± 3.03 −0.71 ± 2.35 −0.59 ± 4.11 0.00 ± 3.71   −0.63 ± 2.68 −0.21 ± 3.48 −0.92 ± 3.00 −0.13 ± 4.94   0.21 ± 3.13 −0.22 ± 3.84 −0.88 ± 2.50 −0.13 ± 1.73  
After                     0.46 ± 2.10 0.17 ± 3.42 0.63 ± 3.26 1.38 ± 1.51  
Following advice                     −0.14 ± 0.65 −0.28 ± 1.43 −0.38 ± 0.72 −0.50 ± 0.93  
Improvement                     −0.07 ± 2.68 0.33 ± 2.44 0.38 ± 2.93 0.25 ± 1.58  

G1: group 1; G2: group 2; G3: group 3; G4: group 4; TMH: tear meniscus height; TBUTF: tear film breakup time first; TBUTA: tear film breakup time average; CNFD: corneal nerve fiber density. Satisfaction: before: pretreatment satisfaction with ocular surface; after: posttreatment satisfaction with ocular surface; following advice: compliance with the doctor's advice; improvement: satisfaction with therapeutic effects. P values of less than 0.05 were considered statistically significant and are expressed as ∗groups 1 versus 3, #groups 1 versus 4, εgroups 2 versus 3, ∂groups 2 versus 4, and ∀groups 3 versus 4 among the different groups.